ID Source | ID |
---|---|
PubMed CID | 665013 |
CHEMBL ID | 1493396 |
CHEBI ID | 92088 |
Synonym |
---|
STL346236 |
3-[6-chloro-4,5-dihydroxy-3-(phenylcarbonyl)-1-benzofuran-7-yl]pentane-2,4-dione |
MLS000040279 , |
smr000045910 |
CBDIVE_006288 |
3-(3-benzoyl-6-chloro-4,5-dihydroxy-1-benzofuran-7-yl)pentane-2,4-dione |
HMS2171D21 |
AKOS022096654 |
CHEMBL1493396 |
3-[6-chloranyl-4,5-bis(oxidanyl)-3-(phenylcarbonyl)-1-benzofuran-7-yl]pentane-2,4-dione |
3-(3-benzoyl-6-chloro-4,5-dihydroxy-7-benzofuranyl)pentane-2,4-dione |
cid_665013 |
3-(3-benzoyl-6-chloro-4,5-dihydroxy-benzofuran-7-yl)pentane-2,4-dione |
bdbm34273 |
CHEBI:92088 |
352553-38-9 |
Q27163882 |
ml016 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 20.0639 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2787 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 4.3688 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 4.3688 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 63.0957 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 15.8489 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 22.9901 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 2.5119 | 0.0126 | 10.6917 | 88.5700 | AID887 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 6.3096 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 4.1095 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 4.1367 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.8489 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 2.5119 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 22.3872 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 15.8489 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
PINK1 | Homo sapiens (human) | Potency | 15.8489 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 31.6228 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 89.1251 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 1.9953 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
Parkin | Homo sapiens (human) | Potency | 15.8489 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
pyruvate kinase | Leishmania mexicana mexicana | Potency | 11.2202 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 7.9433 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 28.1838 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 22.1061 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 0.0018 | 15.6638 | 39.8107 | AID894 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 7.9433 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 39.8107 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 3.9811 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
DNA polymerase beta | Homo sapiens (human) | Potency | 44.6684 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0398 | 16.7842 | 39.8107 | AID995 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.6561 | 9.4520 | 25.1189 | AID927 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 47.7548 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 12.5893 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 25.6651 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 6.3096 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 15.8489 | 0.0200 | 10.7869 | 31.6228 | AID912 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 1.0000 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 8.9125 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Integrin beta-3 | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 1.0000 | 0.0063 | 8.2350 | 39.8107 | AID881 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 6.3096 | 1.5849 | 13.0043 | 25.1189 | AID927 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RNA polymerase beta subunit (EC 2.7.7.6), partial | Escherichia coli | IC50 (µMol) | 50.0000 | 11.6872 | 17.0900 | 23.7759 | AID826 |
MPI protein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.1900 | 13.8256 | 50.1000 | AID1209; AID1220 |
XBP1 | Homo sapiens (human) | IC50 (µMol) | 6.6800 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 5.6700 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |